Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 12/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724629 | 0.79 | GAA (0.50) | MAPTGAARAD52ADORA2AADORA1 | |
| SCHEMBL21761895 | 0.77 | MAPT (0.59) | LMNAOPRM1OPRD1MAPTKMT2A | |
| SCHEMBL16654429 | 0.75 | GAA (0.61) | LMNAOPRM1OPRD1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL28515207 | 0.74 | GAA (0.59) | LMNAOPRM1OPRD1MAPTALDH1A1 | |
| SCHEMBL17728855 | 0.73 | AGPAT2 (0.33) | LMNAMAPTALDH1A1KDM4EGFER | |
| SCHEMBL13548708 | 0.73 | MAPT (0.74) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4772717 | 0.72 | MAPT (0.72) | LMNAOPRM1OPRD1MAPTALDH1A1 | |
| SCHEMBL16655629 | 0.72 | MAPT (0.45) | LMNAOPRM1OPRD1MAPTKMT2A | |
| SCHEMBL2927491 | 0.71 | GAA (0.55) | LMNAOPRM1OPRD1MAPTALDH1A1 | |
| SCHEMBL3534675 | 0.70 | MAPT (0.51) | LMNAOPRM1OPRD1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| EP-3283465-B1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MAN CO LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200317645-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-02 | — | — | US | disclosed |
| US-10562888-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| EP-3421457-A1 | PYRIMIDINE FGFR4 INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| EP-3057943-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| EP-3283465-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9730931-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-01-12 | — | — | US | disclosed |
| WO-2016168331-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-20 | — | — | WO | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| EP-3057943-A1 | PYRIMIDINE FGFR4 INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| WO-2015057938-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | LMNA 4607/4885OPRM1 4490/4885OPRD1 4329/4885 |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | LMNA 4607/4885OPRM1 4490/4885OPRD1 4329/4885 |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | LMNA 4607/4885OPRM1 4490/4885OPRD1 4329/4885 |
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | FGFR4, FGFR1, FGFR3 | LMNA 4605/4885OPRM1 4758/4885OPRD1 4835/4885 |
| US-20200317645-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | FGFR4, FGFR1, FGFR3 | LMNA 4503/4885OPRM1 4654/4885OPRD1 4790/4885 |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | LMNA 4607/4885OPRM1 4490/4885OPRD1 4329/4885 |
| US-10562888-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | FGFR4, FGFR1, FGFR3 | LMNA 4605/4885OPRM1 4758/4885OPRD1 4835/4885 |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | LMNA 4607/4885OPRM1 4490/4885OPRD1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.